CliffBio
small molecule

RISVAN

RISPERIDONE

Loss of exclusivityMay 2031latest FDA-listed patent expiry
CompanyLaboratorios Farmaceuticos Rovi →See this company's full patent-cliff portfolio

Drug detail

Brand nameRISVAN
Active ingredientRISPERIDONE
Strength75MG
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalMarch 2024
Marketing statusDISCN

Listed patents

PatentExpiresType
11752092May 2031use U-3941
11241377May 2031use U-3939
11173110May 2031use U-3941
11007139May 2031use U-3942
10195138May 2031use U-3943
10182982May 2031use U-3943
11759416May 2031use U-3939
11752094May 2031use U-3942
10085936May 2031product
10881605May 2031product
10058504May 2031product
10463607May 2031product
11752093May 2031product
10335366May 2031product

Regulatory exclusivity

CodeExpires
NPMarch 2027

More from Laboratorios Farmaceuticos Rovi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RISVAN patent cliff — loss of exclusivity May 2031 | CliffBio